ArticleJournal of bioethical inquiry2026
Priority-Setting and Values: A Qualitative Study of the Danish Medicines Council.
Article in Journal of bioethical inquiry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
As priority setting committees become commonplace in contemporary welfare states, it becomes increasingly important to understand how they operate. This article contributes to our understanding of contemporary priority setting by examining how the Danish Medicines Council (DMC) makes and justifies its decisions, as well as the role of different (and perhaps conflicting) concerns and values in these decisions. We conducted seventeen interviews with DMC members and observed three DMC meetings spanning five days. Firstly, we find that health-related effect is the most crucial factor in DMC members' recommendations of newly proposed medicines and that discussions of effects take precedence over other considerations in council deliberations. Secondly, we find that the ability of DMC members to adequately assess the effect of newly proposed medicines is often significantly limited by poor data quality and a lack of sufficient documentation, which shifts the DMC's task from making recommendations on an informed basis to providing estimated assessments of the expected effect. In these circumstances of uncertainty about effect, recommendations are influenced by considerations such as the age of patients and the rarity of the disease. This raises significant moral issues in which the DMC has no particular expertise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.